Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLYX-13 in MDD with Inadequate Response
NCT01684163Phase 2Completed
- Sponsor
- Allergan
- Start
- Nov 2012
- Primary completion
- Apr 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rapastinel in major depressive disorder (MDD), sponsored by Allergan. Started Nov 2012; status: completed.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01684163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684163.